Sermorelin - 5MG

Sermorelin evidence summary

Sermorelin is a synthetic 29–amino acid analog of human growth hormone–releasing hormone (GHRH) that stimulates endogenous growth hormone (GH) secretion from the anterior pituitary.^[1] It is the shortest peptide retaining full GHRH biological activity and acts via direct activation of pituitary GHRH receptors to elicit a physiologic, pulsatile GH pattern.^{[1][2][3][4][5]}

Clinical Applications & Effects

• Diagnosis of GH deficiency: IV sermorelin (1 µg/kg) is used as a rapid, relatively specific provocative test in children, with fewer false positives than some alternatives.^[1]
• Treatment of idiopathic GH deficiency: Nightly s.c. sermorelin (30 µg/kg) increases height velocity and supports catch-up growth in prepubertal children over 12–36 months.^[1]
• Aging & body composition: GHRH analogs (incl. sermorelin) can restore age-related declines in GH/IGF-I, increasing lean mass, reducing fat mass, and improving skin thickness—without metabolic/cardiovascular risks typical of exogenous GH therapy.^{[2][3][6][7][8][5]}
• Functional outcomes: Reports include improved well-being, libido, and insulin sensitivity in men; effects on sleep/cognition are variable.^[6][8]
• Safety: Generally well tolerated; transient flushing and injection-site pain are most common. Long-term data show favorable safety without increased tumorigenesis or major metabolic derangements.^[1][3][6]

Pharmacology & Dosing

• Typical pediatric dosing: 30 µg/kg s.c. at bedtime for growth disorders.^[1]
• Adult regimens vary; studies have used ~1–4 mg twice daily for aging-related indications.^[1][7]
• Feedback regulation is preserved with chronic use, lowering risk of sustained supraphysiologic GH exposure.^[2][4][5]

Comparative Efficacy

• Height-velocity gains are typically less than with recombinant GH (somatropin), but sermorelin offers a more physiologic approach suited to select cases.^[1]
• GHRH analogs/GH secretagogues remain effective in aging and some GH-deficient states, but are less effective in hypothalamic deficits or pituitary stalk disconnection.^[9][10]

Emerging & Extra-Endocrine Effects

• Preclinical work suggests cardioprotection, metabolic regulation, immune modulation, and tissue repair potential beyond endocrine indications.^{[3][11][9][5]}

Summary: Sermorelin (10 mg) is a well-tolerated GHRH analog with established roles in diagnosing and treating pediatric GH deficiency and growing evidence for mitigating age-related GH/IGF-I decline, improving body composition, and supporting functional health in older adults. Its physiologic mechanism and safety profile make it a rational alternative to exogenous GH therapy where appropriate.^{[2][3][6][11][4][9][1][7][8][5][10]}

References

1. Prakash A, Goa KL. BioDrugs. 1999;12(2):139-57. doi:10.2165/00063030-199912020-00007.
2. Merriam GR, Schwartz RS, Vitiello MV. Endocrine. 2003;22(1):41-8. doi:10.1385/ENDO:22:1:41.
3. Oikonomakos I, Siow R, Bornstein SR, Steenblock C. Horm Metab Res. 2025. doi:10.1055/a-2641-1207.
4. Merriam GR, Buchner DM, Prinz PN, et al. Endocrine. 1997;7(1):49-52. doi:10.1007/BF02778062.
5. Smith RG, Thorner MO. J Gerontol A Biol Sci Med Sci. 2023;78(Suppl 1):38-43. doi:10.1093/gerona/glad022.
6. Khorram O, Laughlin GA, Yen SS. J Clin Endocrinol Metab. 1997;82(5):1472-9. doi:10.1210/jcem.82.5.3943.
7. Veldhuis JD, Patrie JT, Frick K, et al. J Clin Endocrinol Metab. 2004;89(12):6325-30. doi:10.1210/jc.2004-0430.
8. Vitiello MV, Schwartz RS, Moe KE, et al. Dialogues Clin Neurosci. 2001;3(3):229-36.
9. Muller EE, Rigamonti AE, Colonna Vde G, et al. Neurobiol Aging. 2002;23(5):907-19. doi:10.1016/S0197-4580(02)00026-X.
10. Camanni F, Ghigo E, Arvat E. Front Neuroendocrinol. 1998;19(1):47-72. doi:10.1006/frne.1997.0158.
11. Schally AV, Zhang X, Cai R, et al. Endocrinology. 2019;160(7):1600-1612. doi:10.1210/en.2019-00111.

All COA’s avail upon request by email info@truformlabs.com.

Storage & Handling (Research Use)

• Lyophilized (dry) peptide: Store sealed at −20 °C (long-term). Short-term storage up to 2–3 weeks at 2–8 °C is acceptable.
• After reconstitution: Store at 2–8 °C and use within 7 days, or aliquot into sterile vials and freeze at −20 °C for up to 3 months.
• Light & moisture: Protect from light; keep container tightly closed to avoid moisture uptake.
• Freeze–thaw: Avoid repeated freeze–thaw cycles (use aliquots).
• Solvent compatibility: Choose sterile solvent compatible with your protocol; filter-sterilize if required by your procedures.
• Labeling: Clearly label aliquots with concentration, solvent, and date of preparation.

Storage guidance is general for research peptides and may be adjusted per your lab SOP.